As the government tightens up the controls over sales and possession of research chemicals, scientists are working tirelessly to create new formulas that would be in compliance with the law.
Several recent discoveries have significantly altered the outlooks for independent researchers, including 4F-MPH, Mexedrone and 5-MeO-DiBF.
It is impossible to block progress – as soon as one route of exploration is closed, another is bound to open up. This principle has been on full display in the research chemical market, where strict regulations are making it very difficult to conduct experiments with novel substances while staying within the confines of the law. Despite the legislative setbacks, new options are regularly becoming available to replace the research materials that have been restricted in the UK, giving researchers a chance to continue their work with similar research chemicals. One of the websites specializing for novel research materials, BRC Fine Chemicals, has recently introduced three new products that deserve instant attention, as they replace some of the most popular agents that have been pushed out of the UK market.
4-fluoro-methylphenidate (4F-MPH) is a substance that can provide insight into the group of CNS stimulants, since it is an analogue of the much better known methylphenidate. Just like its closest relative and other phenetylamines, 4F-MPH is believed to affect regulation of neurotransmitters such as dopamine and norepinephrine, with direct impact on transporter molecules. The substance is expected to replicate some of the traits exhibited by ethylphenidate, 3,4-CTMP and 4-Me-TMP, none of which is currently available on the open market.
Due to presence of the 4-fluoro group, new substance could have its specific biochemical profile that can only be precisely determined by laboratory testing in controlled conditions. Since the substance has just arrived to the market and BRC Fine Chemicals is the first website to stock it, peer reviews are still scarce. According to initial reports, this is a highly reactive substance, so precise measurement and systematic monitoring is necessary, and only researchers with state-of-the-art laboratory equipment should consider working with 4F-MPH.
Another exciting product that can currently be ordered only from BRC Fine Chemicals is 5-Meo-DiBF. This compound is structurally similar to hallucinogenic agents from the tryptamine family, and has significant molecular overlapping with research materials such as 5-Meo-DiPT and 5-Meo-DaLT. The main difference is the replacement of the indole nitrogen with an oxygen atom, which identifies the substance with the group of benzofurans, most of which have been placed outside of the legal channels in the UK.
Lacking an indole group, the substance can’t be classified as a true tryptamine, which is why it is not covered by the generic ban on this group of chemicals. By analogy with other research materials, 5-Meo-DiBF is expected to have a strong impact on serotonin receptors. The most important receptors that interact with the substance are 5-HT1 and 5-HT2, even if the strength of impact might not be as powerful as with some of the related substances from the same chemical family.
Many researchers might be happy to learn that an apparent replacement for the popular designer drug mephedrone (4MMC) has been discovered, and it is currently offered under the conveniently similar name ‘Mexedrone’. This is a cathinone-based chemical and shares many of the same entactogenic and stimulant properties with MDMA and other phenetylamines, while remaining completely legal for in vitro experiments. This chemical also causes far less neurotoxicity than some of its relatives, despite high affinity for interaction with the central nervous system.
Mexedrone blocks reuptake of the same neurotransmitters as mephedrone, with the greatest values for dopamine and less pronounced action on serotonin transporter molecules. As a hydrophilic substance, mexedrone has a much lower rate of cell absorption, which should be taken into account when determining proper quantities needed to test biochemical properties of the substance. Mexedrone was first developed in the crystal form, but due to efforts of scientists working on its synthesis a powder form has been made available as well.
Although there was a lot of hype and forum activity for Mexedrone, many initial reports have yet to live up to the expectations of most researchers. While its chemical make-up might be very similar its effects may not.
This article was originally written in English, If you see any errors please email us at words@The-TripReport.com